Fluxome capital
This article was originally published in The Tan Sheet
Executive Summary
Copenhagen-based biotechnology firm Fluxome Sciences secured 100 million Danish krone ($21.3 million under the July 23 conversion rates) in its latest round of financing, the firm announces July 23. Claude J. Stoufs, senior investment manager for Fluxome shareholder Capricorn Venture Partners, says he anticipates the latest capital increase will help Fluxome "become a major player in the field of nutraceutical ingredients based on production by engineered microorganisms." In June, Fluxome announced a partnership with CP Kelco U.S., a division of J.M. Huber, to develop and commercialize fermentation-derived resveratrol for the dietary supplement market, tentatively aiming for a product launch this fall...
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.